Karyopharm has pushed off a debt payment while negotiating with creditors and exploring options for a potential deal, according to the latest company update. The move keeps attention on near-term liquidity and financing pathways for the specialty oncology developer. Elsewhere, Amgen is positioning Imdelltra (tarlatamab) for broader use, signaling an effort to move beyond its initial footprint after earlier clinical success in small-cell lung cancer. The pairing of Karyopharm’s restructuring with Amgen’s expansion plans highlights how quickly strategy shifts across the same oncology value chain. The market focus is likely to remain on whether cash runway can be stabilized for smaller sponsors and whether new label trajectories can translate into durable uptake for larger franchises. The contrast—financial stabilization versus indication broadening—illustrates the two-track reality for biotech investors: execution risk management alongside rapid pipeline-to-market translation.